Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nuria Espinosa

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|March 15, 2022
Immunological and inflammatory changes after simplifying to dual therapy in virologically suppressed HIV-infected patients through week 96 in a randomized trialMaría Trujillo-Rodríguez, Esperanza Muñoz-Muela, Ana Serna-Gallego, et al.
Emerging Microbes & Infections|December 14, 2023
Rat hepatitis E virus (<i>Rocahepevirus ratti</i>) in people living with HIVMaría Casares-Jimenez, Antonio Rivero-Juarez, Pedro Lopez-Lopez, et al.
The Journal of Antimicrobial Chemotherapy|August 7, 2023
Decay kinetics of HIV-1-RNA in seminal plasma with dolutegravir/lamivudine versus dolutegravir plus emtricitabine/tenofovir alafenamide in treatment-naive people living with HIVAbraham Saborido-Alconchel, Ana Serna-Gallego, Luis E Lopez-Cortes, et al.
Plos One|July 26, 2018
Relapse or reinfection after failing hepatitis C direct acting antiviral treatment: Unravelled by phylogenetic analysisLize Cuypers, Ana Belén Pérez, Natalia Chueca, et al.
Antimicrobial Agents and Chemotherapy|June 24, 2020
Modulation of Monocyte Activation and Function during Direct Antiviral Agent Treatment in Patients Coinfected with HIV and Hepatitis C VirusRebeca S De Pablo-Bernal, M Reyes Jimenez-Leon, Laura Tarancon-Diez, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|October 5, 2025
Randomized clinical trial to evaluate the longitudinal HIV-1 reservoir and inflammation in treatment-naïve people starting dolutegravir/lamivudine versus dolutegravir plus tenofovir alafenamide/emtricitabineAbraham Saborido-Alconchel, Ana Serna-Gallego, María Trujillo-Rodriguez, et al.
HIV Research & Clinical Practice|August 19, 2021
eGFR-EPI changes among HIV patients who switch from F/TDF to F/TAF while maintaining the same third agent in the Spanish VACH cohortRamón Teira, Helena Diaz-Cuervo, Filipa Aragão, et al.
Plos One|May 20, 2016
Hepatic Safety of Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate Fixed-Dose Single-Tablet Regimen in HIV-Infected Patients with Active Hepatitis C Virus Infection: The hEPAtic StudyKarin Neukam, Nuria Espinosa, Antonio Collado, et al.
Infectious Diseases and Therapy|April 11, 2022
Shorter Time to Discontinuation Due to Treatment Failure in People Living with HIV Switched to Dolutegravir Plus Either Rilpivirine or Lamivudine Compared with Integrase Inhibitor-Based Triple Therapy in a Large Spanish CohortRamón Teira, Helena Diaz-Cuervo, Filipa Aragão, et al.
Ebiomedicine|April 5, 2023
Toll-like receptor agonists enhance HIV-specific T cell response mediated by plasmacytoid dendritic cells in diverse HIV-1 disease progression phenotypesMaria R Jimenez-Leon, Carmen Gasca-Capote, Laura Tarancon-Diez, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|March 15, 2022
Immunological and inflammatory changes after simplifying to dual therapy in virologically suppressed HIV-infected patients through week 96 in a randomized trialMaría Trujillo-Rodríguez, Esperanza Muñoz-Muela, Ana Serna-Gallego, et al.
Emerging Microbes & Infections|December 14, 2023
Rat hepatitis E virus (<i>Rocahepevirus ratti</i>) in people living with HIVMaría Casares-Jimenez, Antonio Rivero-Juarez, Pedro Lopez-Lopez, et al.
The Journal of Antimicrobial Chemotherapy|August 7, 2023
Decay kinetics of HIV-1-RNA in seminal plasma with dolutegravir/lamivudine versus dolutegravir plus emtricitabine/tenofovir alafenamide in treatment-naive people living with HIVAbraham Saborido-Alconchel, Ana Serna-Gallego, Luis E Lopez-Cortes, et al.
Plos One|July 26, 2018
Relapse or reinfection after failing hepatitis C direct acting antiviral treatment: Unravelled by phylogenetic analysisLize Cuypers, Ana Belén Pérez, Natalia Chueca, et al.
Antimicrobial Agents and Chemotherapy|June 24, 2020
Modulation of Monocyte Activation and Function during Direct Antiviral Agent Treatment in Patients Coinfected with HIV and Hepatitis C VirusRebeca S De Pablo-Bernal, M Reyes Jimenez-Leon, Laura Tarancon-Diez, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|October 5, 2025
Randomized clinical trial to evaluate the longitudinal HIV-1 reservoir and inflammation in treatment-naïve people starting dolutegravir/lamivudine versus dolutegravir plus tenofovir alafenamide/emtricitabineAbraham Saborido-Alconchel, Ana Serna-Gallego, María Trujillo-Rodriguez, et al.
HIV Research & Clinical Practice|August 19, 2021
eGFR-EPI changes among HIV patients who switch from F/TDF to F/TAF while maintaining the same third agent in the Spanish VACH cohortRamón Teira, Helena Diaz-Cuervo, Filipa Aragão, et al.
Plos One|May 20, 2016
Hepatic Safety of Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate Fixed-Dose Single-Tablet Regimen in HIV-Infected Patients with Active Hepatitis C Virus Infection: The hEPAtic StudyKarin Neukam, Nuria Espinosa, Antonio Collado, et al.
Infectious Diseases and Therapy|April 11, 2022
Shorter Time to Discontinuation Due to Treatment Failure in People Living with HIV Switched to Dolutegravir Plus Either Rilpivirine or Lamivudine Compared with Integrase Inhibitor-Based Triple Therapy in a Large Spanish CohortRamón Teira, Helena Diaz-Cuervo, Filipa Aragão, et al.
Ebiomedicine|April 5, 2023
Toll-like receptor agonists enhance HIV-specific T cell response mediated by plasmacytoid dendritic cells in diverse HIV-1 disease progression phenotypesMaria R Jimenez-Leon, Carmen Gasca-Capote, Laura Tarancon-Diez, et al.
Pageof 6